Trial Profile
Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naive Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin neutral protamine lispro/insulin lispro (Primary) ; Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CONFIDENCE
Most Recent Events
- 01 Apr 2022 Results (n=100) assessing the association between variant rs163184 in the type 2 diabetes mellitus susceptibility gene KCNQ1 and exenatide glycemic response in the Chinese population, published in the Pharmacogenomics.
- 01 Aug 2015 Primary endpoint has been met. (Comparison Between Treatment Group (exenatide versus pioglitazone) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.
- 01 Aug 2015 Primary endpoint has not been met. (Comparison Between Treatment Group (exenatide versus insulin) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.